Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +55.6 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594728 |
| 2 | = | Malignant Vulvar Neoplasm | +22.2 | 96.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594729 |
| 3 | = | Cutaneous Melanoma | +14.8 | 92.6 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594730 |
| 3 | = | Malignant Vaginal Neoplasm | +14.8 | 92.6 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594731 |
| 5 | = | Malignant Ovarian Neoplasm | +14.8 | 85.2 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594732 |
| 6 | = | Malignant Bladder Neoplasm | +11.2 | 81.5 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594733 |
| 7 | = | Malignant Laryngeal Neoplasm | +11.1 | 77.8 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594734 |
| 8 | = | Malignant Pancreatic Neoplasm | +7.4 | 74.1 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594735 |
| 9 | = | Malignant Kidney Neoplasm | +3.7 | 70.4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594736 |
| 9 | = | Malignant Thyroid Gland Neoplasm | +3.7 | 70.4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594737 |
| 11 | = | Malignant Breast Neoplasm | 0 | 63 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594738 |
| 11 | = | Malignant Lung Neoplasm | 0 | 63 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594739 |
| 11 | = | Malignant Rectal Neoplasm | 0 | 63 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594740 |
| 14 | = | Malignant Salivary Gland Neoplasm | -3.7 | 51.9 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594741 |
| 15 | = | Malignant Hypopharyngeal Neoplasm | -3.7 | 48.1 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594742 |
| 16 | = | Malignant Central Nervous System Neoplasm | -3.7 | 44.4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594743 |
| 16 | = | Malignant Gastric Neoplasm | -3.7 | 44.4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594744 |
| 18 | = | Multiple Myeloma | -7.4 | 37 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594745 |
| 19 | = | Malignant Cervical Neoplasm | -7.4 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594747 |
| 19 | = | Malignant Mesothelioma | -7.4 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594746 |
| 21 | = | Malignant Anal Neoplasm | -7.4 | 25.9 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594748 |
| 22 | = | Malignant Uterine Corpus Neoplasm | -7.5 | 22.2 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594749 |
| 23 | = | Non-Hodgkin Lymphoma | -11.1 | 18.5 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594750 |
| 24 | = | Hodgkin Lymphoma | -11.1 | 14.8 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594751 |
| 25 | = | Leukemia | -11.1 | 11.1 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594752 |
| 26 | = | Malignant Liver Neoplasm | -14.8 | 7.4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594753 |
| 27 | = | Malignant Esophageal Neoplasm | -22.3 | 3.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594754 |
| 28 | = | Malignant Nasopharyngeal Neoplasm | -37 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2594755 |
Data updated 16 hours agoSource updated unknown28 eligible entities · inputs hash a0327bdcfb0803b723f6eb2a